Evidence map›Paper›PMID 32981648›Full record

ReviewRheumatic diseases clinics of North America2020

Increasing Ancestral Diversity in Lupus Trials: Ways Forward.

Titilola Falasinnu, Yashaar Chaichian, Julia F Simard

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatic diseases clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Titilola FalasinnuDepartment of Epidemiology and Population Health, Stanford Medicine, 150 Governor's Lane, Stanford, CA, USA; Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford Medicine, 150 Governor's Lane, Stanford, CA, USA. Electronic address: tof@stanford.edu.
Yashaar ChaichianDivision of Immunology and Rheumatology, Department of Medicine, Stanford Medicine, Stanford, CA, USA.
Julia F SimardDepartment of Epidemiology and Population Health, Stanford Medicine, 150 Governor's Lane, Stanford, CA, USA; Division of Immunology and Rheumatology, Department of Medicine, Stanford Medicine, 150 Governor's Lane, Stanford, CA, USA.

Funding

Interdisciplinary Research Training in Pain and Substance Use DisordersT32DA035165 · NIDA · STANFORD UNIVERSITY · PI SEAN C MACKEY · 2013 to 2026
$7.2M
NIDA NIH HHS T32 DA035165
6 · The paper itself

Abstract

Significant disparities exist in systemic lupus erythematosus (SLE) regarding prevalence, disease severity, and mortality, with race/ethnic minorities being disproportionately affected in the United States. This review highlights that despite these disparities, race/ethnic minority underrepresentation remains an issue within SLE research. Decreased race/ethnic minority involvement in SLE research has real-world implications, including less understanding of the disease and less applicability of approved therapies among diverse groups of patients. Members of the SLE research community have an obligation to narrow this gap to ensure that future advances within the field are derived from and benefit a more representative group of patients.

Indexed as

Clinical Trials as TopicHealthcare DisparitiesHealth Status DisparitiesLupus Erythematosus, SystemicPatient SelectionEthnicityHumansMinority GroupsUnited StatesVulnerable PopulationsBiomedical studiesClinical trialsDiversityHealth disparitiesHeterogeneityLupusTreatment response

Identifiers

PMID32981648
PMCPMC11075620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.